<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311010</url>
  </required_header>
  <id_info>
    <org_study_id>BE-02-RG-234</org_study_id>
    <secondary_id>2011-004276-11</secondary_id>
    <nct_id>NCT02311010</nct_id>
  </id_info>
  <brief_title>Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism</brief_title>
  <acronym>CYRANO</acronym>
  <official_title>Influence of Recipient Cytochrome P450 3A5 Polymorphism on the Metabolism of Prolonged Release Tacrolimus Administered de Novo After Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after
      kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of
      the genetic Cyp 450 3A5 polymorphism of the recipient.

      The study of the tacrolimus through level (ng/ml) determines if the therapeutic level is
      reached.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of tacrolimus</measure>
    <time_frame>1 year</time_frame>
    <description>tacrolimus level (ng/ml) at C0 every 3 days during 2 weeks and thereafter every month during 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney graft function</measure>
    <time_frame>1 year</time_frame>
    <description>serum creatinine level (mg/dl) and GFR (ml/min)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Administration strategy</measure>
    <time_frame>first day</time_frame>
    <description>starting tacrolimus daily dose (mg/kg/d) accorded to CYP 3A5 polymorphism of the recipient</description>
  </other_outcome>
  <other_outcome>
    <measure>New onset of diabetes after transplantation (NODAT)</measure>
    <time_frame>1 year</time_frame>
    <description>fasting glycemia (mg/dl) HbA1C (%)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>CYP 3 A 5 *3/*3 control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CYP 3 A 5 *3/*3 control group will receive 0,20 mg/kg of Advagraf®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP 3 A 5 *3/*3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP 3 A 5 *3/*3 will receive 0,25 mg/kg of Advagraf®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP 3 A 5 *1/*3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP 3 A 5 *1/*3 will receive 0,30 mg/kg of Advagraf®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP 3 A 5 *1/*1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP 3 A 5 *1/*1 will receive 0,35 mg/kg of Advagraf®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf</intervention_name>
    <description>daily dose adapted according to Cyp 3A5 polymorphism</description>
    <arm_group_label>CYP 3 A 5 *3/*3</arm_group_label>
    <arm_group_label>CYP 3 A 5 *1/*3</arm_group_label>
    <arm_group_label>CYP 3 A 5 *1/*1</arm_group_label>
    <other_name>Tacrolimus prolonged release formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First or second Kidney Transplantation from deceased or living donor

        Exclusion Criteria:

          -  Donor age &lt; 5 years.

          -  Patients who require plasma exchange because of high immunological risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc Université Catholique de Louvain</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Prof Martine De Meyer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>transplant</keyword>
  <keyword>immunosuppressive drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

